The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
